{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:54:08Z","timestamp":1790646848410,"version":"4.1.0"},"reference-count":253,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The pioneering discovery by Yamanaka and colleagues enabling the reprogramming of terminally differentiated somatic cells into induced pluripotent stem cells (iPSCs) has opened transformative opportunities for disease modeling and regenerative medicine, particularly in the context of inherited monogenic disorders. Patient-specific iPSCs can be generated, expanded almost indefinitely, and differentiated into a broad spectrum of cell types, including hematopoietic stem and progenitor cells, mature myeloid cells, and leukemic cells. Despite important limitations \u2013 such as epigenetic memory, variable differentiation efficiency, and concerns regarding tumorigenicity \u2013 iPSCs have become an indispensable experimental platform for studying inherited hematological disorders and malignancies, providing a renewable and physiologically relevant source of cells for downstream analyses. Beyond their research applications, iPSC-derived blood cells are increasingly being explored in preclinical studies and early-phase clinical trials as potential therapeutic products. The advent of CRISPR\/Cas9 genome editing, pioneered by Charpentier and Doudna, has further advanced iPSC-based models by enabling precise correction or introduction of disease-causing mutations and the generation of isogenic control lines. This approach facilitates detailed mechanistic studies of defective hematopoiesis, enables drug discovery and repurposing through\n                    <jats:italic>in silico<\/jats:italic>\n                    screening platforms \u2013 such as L1000CDS\n                    <jats:sup>2<\/jats:sup>\n                    and the Connectivity Map \u2013 and supports preclinical therapeutic validation. In this review, we summarize key applications of iPSC technology in hemato-oncology, discuss its major advantages and current limitations, and highlight emerging directions, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1815809","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:21:56Z","timestamp":1784089316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Modeling myeloid cell development in health and disease using induced pluripotent stem cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Ivan","family":"Tesakov","sequence":"first","affiliation":[{"name":"Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Nasri","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim","family":"Klimiankou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bet\u00fcl","family":"Findik","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Loskill","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Eberhard Karls University Tuebingen","place":["Tuebingen, Germany"]},{"name":"NMI Natural and Medical Sciences Institute at the University of Tuebingen","place":["Reutlingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Skokowa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, Clinical Immunology, and Rheumatology, University Hospital Tuebingen","place":["Tuebingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1089\/scd.2013.0265","article-title":"Humanized mice as a model to study human hematopoietic stem cell transplantation","volume":"23","author":"Tanner","year":"2014","journal-title":"Stem Cells Dev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: Differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3324\/haematol.2018.196105","article-title":"Peering through zebrafish to understand inherited bone marrow failure syndromes","volume":"104","author":"Oyarbide","year":"2019","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.240200","article-title":"A zebrafish model for HAX1-associated congenital neutropenia","volume":"106","author":"Doll","year":"2020","journal-title":"Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011656","article-title":"A JAGN1- associated severe congenital neutropenia zebrafish model revealed an altered G-CSFR signaling and UPR activation","volume":"8","author":"Doll","year":"2024","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2016.11.018","article-title":"Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease","volume":"20","author":"Chao","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.stem.2017.01.009","article-title":"Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia","volume":"20","author":"Kotini","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1811609","article-title":"Senescence impairs successful reprogramming to pluripotent stem cells","volume":"23","author":"Banito","year":"2009","journal-title":"Genes Dev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1374","article-title":"Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts","volume":"26","author":"Nakagawa","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.stem.2019.10.002","article-title":"Excluding Oct4 from Yamanaka cocktail unleashes the developmental potential of iPSCs","volume":"25","author":"Velychko","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904825106","article-title":"Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation","volume":"106","author":"Papapetrou","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1502","article-title":"Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2","volume":"26","author":"Huangfu","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00348","article-title":"Generation of urine cell-derived non-integrative human iPSCs and iNSCs: A step-by-step optimized protocol","volume":"10","author":"Cheng","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2022.102902","article-title":"Establishment of four induced pluripotent stem cell lines from CD34+ hematopoietic stem and progenitor cells from a patient diagnosed with an invasive lobular mammary carcinoma","volume":"64","author":"Keller","year":"2022","journal-title":"Stem Cell Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027956","article-title":"Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors","volume":"6","author":"Mack","year":"2011","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071596","article-title":"Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation","volume":"8","author":"Bedel","year":"2013","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.exphem.2018.11.006","article-title":"Modeling myeloid Malignancies with patient-derived iPSCs","volume":"71","author":"Papapetrou","year":"2019","journal-title":"Exp Hematol"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1007\/7651_2021_349","article-title":"Derivation of clinical-grade induced pluripotent stem cell lines from erythroid progenitor cells in xenofree conditions","volume-title":"Induced Pluripotent Stem (Ips) Cells","author":"Singh","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101620","article-title":"Generation of transgene-free human induced pluripotent stem cells from erythroblasts in feeder-free conditions","volume":"3","author":"Perriot","year":"2022","journal-title":"STAR Protoc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2013.0621","article-title":"Vectorology and factor delivery in induced pluripotent stem cell reprogramming","volume":"23","author":"Hu","year":"2014","journal-title":"Stem Cells Dev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131128","article-title":"Effects of integrating and non-integrating reprogramming methods on copy number variation and genomic stability of human induced pluripotent stem cells","volume":"10","author":"Kang","year":"2015","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.85.348","article-title":"Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome","volume":"85","author":"Fusaki","year":"2009","journal-title":"Proc Jpn Acad Ser B"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1103509108","article-title":"Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors","volume":"108","author":"Ban","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2011.12","article-title":"Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures","volume":"21","author":"Chou","year":"2011","journal-title":"Cell Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.08.012","article-title":"Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA","volume":"7","author":"Warren","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2009.05.005","article-title":"Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins","volume":"4","author":"Kim","year":"2009","journal-title":"Cell Stem Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2024.103332","article-title":"Generation of iPSC lines derived from skin fibroblasts of two healthy controls using non-transmissible form of Sendai virus","volume":"76","author":"Orsi","year":"2024","journal-title":"Stem Cell Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502573200","article-title":"Transcriptional regulation of nanog by OCT4 and SOX2","volume":"280","author":"Rodda","year":"2005","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.08.020","article-title":"Core transcriptional regulatory circuitry in human embryonic stem cells","volume":"122","author":"Boyer","year":"2005","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.041","article-title":"A bivalent chromatin structure marks key developmental genes in embryonic stem cells","volume":"125","author":"Bernstein","year":"2006","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.02.043","article-title":"Epigenetics of reprogramming to induced pluripotency","volume":"152","author":"Papp","year":"2013","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.02.005","article-title":"Replacement of Oct4 by Tet1 during iPSC induction reveals an important role of DNA methylation and hydroxymethylation in reprogramming","volume":"12","author":"Gao","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature09342","article-title":"Epigenetic memory in induced pluripotent stem cells","volume":"467","author":"Kim","year":"2010","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1667","article-title":"Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells","volume":"28","author":"Polo","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szad022","article-title":"Reprogramming of acute myeloid leukemia patients cells: Harboring cancer mutations requires targeting of AML hierarchy","volume":"12","author":"Golubeva","year":"2023","journal-title":"Stem Cells Transl Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/2159-8290.CD-16-1049","article-title":"Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2 - and TET2 -mutant acute myeloid leukemia","volume":"7","author":"Shih","year":"2017","journal-title":"Cancer Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.2000.9912","article-title":"Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture","volume":"227","author":"Amit","year":"2000","journal-title":"Dev Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.102.012583","article-title":"Human feeder layers for human embryonic stem cells1","volume":"68","author":"Amit","year":"2003","journal-title":"Biol Reprod"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2015.01.005","article-title":"Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies","volume":"4","author":"Lachmann","year":"2015","journal-title":"Stem Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101400","article-title":"Generation, expansion, and drug treatment of hematopoietic progenitor cells derived from human iPSCs","volume":"3","author":"Dannenmann","year":"2022","journal-title":"STAR Protoc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13189","article-title":"Influence of feeder cells on transcriptomic analysis of pluripotent stem cells","volume":"55","author":"Wan","year":"2022","journal-title":"Cell Proliferation"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.12.050","article-title":"A defined xeno-free and feeder-free culture system for the derivation, expansion and direct differentiation of transgene-free patient-specific induced pluripotent stem cells","volume":"35","author":"Lu","year":"2014","journal-title":"Biomaterials"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1177","article-title":"Derivation of human embryonic stem cells in defined conditions","volume":"24","author":"Ludwig","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1593","article-title":"Chemically defined conditions for human iPSC derivation and culture","volume":"8","author":"Chen","year":"2011","journal-title":"Nat Methods"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/9704945","article-title":"Laminin as a potent substrate for large-scale expansion of human induced pluripotent stem cells in a closed cell expansion system","volume":"2019","author":"Paccola Mesquita","year":"2019","journal-title":"Stem Cells Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.14573\/altex.2112204","article-title":"Comparison of human recombinant protein coatings and fibroblast-ECM to Matrigel for induced pluripotent stem cell culture and renal podocyte differentiation","volume":"40","author":"Murphy","year":"2023","journal-title":"ALTEX"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017829","article-title":"A defined, feeder-free, serum-free system to generate in vitro hematopoietic progenitors and differentiated blood cells from hESCs and hiPSCs","volume":"6","author":"Salvagiotto","year":"2011","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2020.07.009","article-title":"Direct comparison of four hematopoietic differentiation methods from human induced pluripotent stem cells","volume":"15","author":"Tursky","year":"2020","journal-title":"Stem Cell Rep"},{"key":"B52","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13287-020-01997-w","article-title":"Multilineage differentiation potential of hematoendothelial progenitors derived from human induced pluripotent stem cells","volume":"11","author":"Netsrithong","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2021.05.018","article-title":"Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium","volume":"16","author":"Vaughan-Jackson","year":"2021","journal-title":"Stem Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2012.130","article-title":"Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions","volume":"7","author":"Beers","year":"2012","journal-title":"Nat Protoc"},{"key":"B55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.reth.2016.12.003","article-title":"Visualization of morphological categories of colonies for monitoring of effect on induced pluripotent stem cell culture status","volume":"6","author":"Nagasaka","year":"2017","journal-title":"Regenerative Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2018-0095","article-title":"Quality control guidelines for clinical-grade human induced pluripotent stem cell lines","volume":"13","author":"Sullivan","year":"2018","journal-title":"Regener Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v11.i10.729","article-title":"Genomic integrity of human induced pluripotent stem cells: Reprogramming, differentiation and applications","volume":"11","author":"Steichen","year":"2019","journal-title":"WJSC"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-1084-8_15","article-title":"Evaluating reprogramming efficiency and pluripotency of the established human iPSCS by pluripotency markers","volume-title":"Nuclear Reprogramming","author":"Cevallos","year":"2021"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2023.08.003","article-title":"ISSCR standards for the use of human stem cells in basic research","volume":"18","author":"Ludwig","year":"2023","journal-title":"Stem Cell Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1890","article-title":"Recurrent copy number variations in human induced pluripotent stem cells","volume":"29","author":"Martins-Taylor","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12015-016-9680-6","article-title":"Genomic instability of iPSCs: Challenges towards their clinical applications","volume":"13","author":"Yoshihara","year":"2017","journal-title":"Stem Cell Rev Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.stemcr.2019.12.004","article-title":"Recurrent genetic abnormalities in human pluripotent stem cells: Definition and routine detection in culture supernatant by targeted droplet digital PCR","volume":"14","author":"Assou","year":"2020","journal-title":"Stem Cell Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2020-0147","article-title":"Chromosomal aberrations after induced pluripotent stem cells reprogramming","volume":"44","author":"Vaz","year":"2021","journal-title":"Genet Mol Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"17201","DOI":"10.1038\/s41598-018-35506-0","article-title":"Need for high-resolution genetic analysis in iPSC: Results and lessons from the ForIPS Consortium","volume":"8","author":"Popp","year":"2018","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0167","article-title":"Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia","volume":"4","author":"Kotini","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.12.032","article-title":"Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines","volume":"144","author":"Bock","year":"2011","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.07.001","article-title":"Genetic and epigenetic variations in iPSCs: Potential causes and implications for application","volume":"13","author":"Liang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature22403","article-title":"Common genetic variation drives molecular heterogeneity in human iPSCs","volume":"546","author":"Kilpinen","year":"2017","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005793","article-title":"Genetic variation, not cell type of origin, underlies the majority of identifiable regulatory differences in iPSCs","volume":"12","author":"Burrows","year":"2016","journal-title":"PloS Genet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2017.03.009","article-title":"Large-scale profiling reveals the influence of genetic variation on gene expression in human induced pluripotent stem cells","volume":"20","author":"DeBoever","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.042317","article-title":"Addressing variability in iPSC-derived models of human disease: Guidelines to promote reproducibility","volume":"13","author":"Volpato","year":"2020","journal-title":"Dis Models Mech"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2332","article-title":"Molecular analysis of neutrophil differentiation from human induced pluripotent stem cells delineates the kinetics of key regulators of hematopoiesis","volume":"34","author":"Sweeney","year":"2016","journal-title":"Stem Cells"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416087","article-title":"iPSC-derived macrophages: The differentiation protocol affects cell immune characteristics and differentiation trajectories","volume":"23","author":"Klepikova","year":"2022","journal-title":"IJMS"},{"key":"B74","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.stem.2021.03.023","article-title":"iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia","volume":"28","author":"Dannenmann","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047704","article-title":"Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures","volume":"109","author":"Kennedy","year":"2007","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1242\/dev.011767","article-title":"The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF","volume":"135","author":"Pearson","year":"2008","journal-title":"Development"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2008-0922","article-title":"Hematopoietic and endothelial differentiation of human induced pluripotent stem cells","volume":"27","author":"Choi","year":"2009","journal-title":"Stem Cells"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074120","article-title":"Short-term BMP-4 treatment initiates mesoderm induction in human embryonic stem cells","volume":"111","author":"Zhang","year":"2008","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2915","article-title":"Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells","volume":"32","author":"Sturgeon","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.581331","article-title":"Initial WNT\/\u03b2-catenin activation enhanced mesoderm commitment, extracellular matrix expression, cell aggregation and cartilage tissue yield from induced pluripotent stem cells","volume":"8","author":"Kreuser","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2012.0053","article-title":"Activin A promotes hematopoietic fated mesoderm development through upregulation of Brachyury in human embryonic stem cells","volume":"21","author":"Cerdan","year":"2012","journal-title":"Stem Cells Dev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.228064","article-title":"A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification","volume":"106","author":"Ackermann","year":"2020","journal-title":"Haematol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.4.1357","article-title":"The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: Synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors","volume":"181","author":"Jacobsen","year":"1995","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2260","article-title":"Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand","volume":"90","author":"Haylock","year":"1997","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2283045.x","article-title":"Thrombopoietin alone stimulates the early proliferation and survival of human erythroid, myeloid and multipotential progenitors in serum\u2010free culture","volume":"98","author":"Yoshida","year":"1997","journal-title":"Br J Haematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400588","article-title":"Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand","volume":"11","author":"Ohmizono","year":"1997","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8583","article-title":"Expansion of human NOD\/SCID-repopulating cells by stem cell factor, Flk2\/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor","volume":"105","author":"Ueda","year":"2000","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0092-8674(82)90376-2","article-title":"Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy","volume":"28","author":"Tushinski","year":"1982","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1084\/jem.165.4.941","article-title":"Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates","volume":"165","author":"Welte","year":"1987","journal-title":"J Exp Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.03.002","article-title":"Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and \u2018emergency\u2019 hematopoiesis","volume":"42","author":"Panopoulos","year":"2008","journal-title":"Cytokine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2020.100075","article-title":"Generation of human neutrophils from induced pluripotent stem cells in chemically defined conditions using ETV2 modified mRNA","volume":"1","author":"Majumder","year":"2020","journal-title":"STAR Protoc"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2019.11.005","article-title":"Inducible forward programming of human pluripotent stem cells to hemato-endothelial progenitor cells with hematopoietic progenitor potential","volume":"14","author":"Lange","year":"2020","journal-title":"Stem Cell Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s004410051254","article-title":"Op\/op mice defective in production of functional colony-stimulating factor-1 lack macrophages in muscularis externa of the small intestine","volume":"295","author":"Mikkelsen","year":"1999","journal-title":"Cell Tissue Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41598-018-20491-1","article-title":"Secretory factors from OP9 stromal cells delay differentiation and increase the expansion potential of adult erythroid cells in vitro","volume":"8","author":"Trakarnsanga","year":"2018","journal-title":"Sci Rep"},{"key":"B95","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nprot.2010.184","article-title":"Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells","volume":"6","author":"Choi","year":"2011","journal-title":"Nat Protoc"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2022.42.4.457","article-title":"Erythroid differentiation of induced pluripotent stem cells co-cultured with OP9 cells for diagnostic purposes","volume":"42","author":"Roh","year":"2022","journal-title":"Ann Lab Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058123","article-title":"OP9 bone marrow stroma cells differentiate into megakaryocytes and platelets","volume":"8","author":"Matsubara","year":"2013","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22456","article-title":"Neutrophil differentiation from human\u2010induced pluripotent stem cells","volume":"226","author":"Morishima","year":"2011","journal-title":"J Cell Physiol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-160838","article-title":"Derivation of functional mature neutrophils from human embryonic stem cells","volume":"113","author":"Yokoyama","year":"2009","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1089\/biores.2014.0045","article-title":"Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells: Ex vivo models of X0 -linked, AR220 - and AR470 - chronic granulomatous diseases","volume":"3","author":"Brault","year":"2014","journal-title":"Biores Open Access"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759558","article-title":"Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells","volume":"12","author":"Netsrithong","year":"2021","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.02.011","article-title":"T-cell potential and development in vitro: the OP9-DL1 approach","volume":"19","author":"De Pooter","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203189","article-title":"Age-associated changes in the differentiation potentials of human circulating hematopoietic progenitors to T- or NK-lineage cells","volume":"190","author":"Kyoizumi","year":"2013","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003827","article-title":"Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling","volume":"10","author":"Makino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.3791\/2559","article-title":"Modified ES\/OP9 co-culture protocol provides enhanced characterization of hematopoietic progeny","volume":"52","author":"Lynch","year":"2011","journal-title":"JoVE"},{"key":"B106","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/BF03401776","article-title":"Differentiation of human embryonic stem cells into embryoid bodies comprising the three embryonic germ layers","volume":"6","author":"Itskovitz-Eldor","year":"2000","journal-title":"Mol Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v1.i1.11","article-title":"Embryoid body formation from embryonic and induced pluripotent stem cells: benefits of bioreactors","volume":"1","author":"Rungarunlert","year":"2009","journal-title":"WJSC"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2014.0427","article-title":"Engineering strategies for the formation of embryoid bodies from human pluripotent stem cells","volume":"24","author":"Pettinato","year":"2015","journal-title":"Stem Cells Dev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4522","article-title":"Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development","volume":"106","author":"Zambidis","year":"2005","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2015.12.009","article-title":"Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential","volume":"6","author":"Kytt\u00e4l\u00e4","year":"2016","journal-title":"Stem Cell Rep"},{"key":"B111","doi-asserted-by":"publisher","first-page":"55196","DOI":"10.3791\/55196","article-title":"Directed differentiation of primitive and definitive hematopoietic progenitors from human pluripotent stem cells","volume":"129","author":"Dege","year":"2017","journal-title":"JoVE"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2016.12.020","article-title":"Human induced pluripotent stem cell-derived macrophages share ontogeny with MYB-independent tissue-resident macrophages","volume":"8","author":"Buchrieser","year":"2017","journal-title":"Stem Cell Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3387","article-title":"A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells","volume":"33","author":"Tsankov","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"8547","DOI":"10.1038\/s41467-024-52922-1","article-title":"Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control","volume":"15","author":"Dobner","year":"2024","journal-title":"Nat Commun"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0832","article-title":"Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells","volume":"102","author":"Chadwick","year":"2003","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/scrt222","article-title":"Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells","volume":"4","author":"Lim","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"B117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2018.12.005","article-title":"Development of innate immune cells from human pluripotent stem cells","volume":"71","author":"Bernareggi","year":"2019","journal-title":"Exp Hematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-0987","article-title":"Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation","volume":"106","author":"Ng","year":"2005","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/9780470151808.sc01d03s4","article-title":"Directed differentiation of human embryonic stem cells as spin embryoid bodies and a description of the hematopoietic blast colony forming assay","volume":"4","author":"Ng","year":"2008","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2020.100130","article-title":"Protocol for the generation of definitive hematopoietic progenitors from human pluripotent stem cells","volume":"1","author":"Nafria","year":"2020","journal-title":"STAR Protoc"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071098","article-title":"Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions","volume":"8","author":"Wilgenburg","year":"2013","journal-title":"PloS One"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-021-00654-7","article-title":"Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors","volume":"17","author":"Ackermann","year":"2022","journal-title":"Nat Protoc"},{"key":"B123","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1038\/s41467-018-07570-7","article-title":"Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections","volume":"9","author":"Ackermann","year":"2018","journal-title":"Nat Commun"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1719452","article-title":"Robust, scalable and xeno-free protocol for differentiating human induced pluripotent stem cells into functional macrophages","volume":"16","author":"De Homdedeu","year":"2026","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41419-022-04850-5","article-title":"Defective hematopoietic differentiation of immune aplastic anemia patient-derived iPSCs","volume":"13","author":"Tellechea","year":"2022","journal-title":"Cell Death Dis"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022261","article-title":"A novel serum-free monolayer culture for orderly hematopoietic differentiation of human pluripotent cells via mesodermal progenitors","volume":"6","author":"Niwa","year":"2011","journal-title":"PloS One"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059243","article-title":"Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions","volume":"8","author":"Yanagimachi","year":"2013","journal-title":"PloS One"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243807","article-title":"Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterparts","volume":"15","author":"Monkley","year":"2020","journal-title":"PloS One"},{"key":"B129","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.06.017","article-title":"Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function","volume":"47","author":"Takata","year":"2017","journal-title":"Immunity"},{"key":"B130","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13287-023-03547-6","article-title":"Comparison of osteoclast differentiation protocols from human induced pluripotent stem cells of different tissue origins","volume":"14","author":"Bl\u00fcmke","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112858","article-title":"Assessment of the hematopoietic differentiation potential of human pluripotent stem cells in 2D and 3D culture systems","volume":"10","author":"Mora-Roldan","year":"2021","journal-title":"Cells"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1038\/ncomms5372","article-title":"Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators","volume":"5","author":"Elcheva","year":"2014","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14010","article-title":"Concise review: programming human pluripotent stem cells into blood","volume":"173","author":"Easterbrook","year":"2016","journal-title":"Br J Haematol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.640703","article-title":"Macrophages derived from human induced pluripotent stem cells: the diversity of protocols, future prospects, and outstanding questions","volume":"9","author":"Lyadova","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2024.03.006","article-title":"Forward programming human pluripotent stem cells into microglia","volume":"34","author":"Csat\u00e1ri","year":"2024","journal-title":"Trends Cell Biol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/cpsc.108","article-title":"Generation and functional characterization of monocytes and macrophages derived from human induced pluripotent stem cells","volume":"52","author":"Cao","year":"2020","journal-title":"CP Stem Cell Biol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"17394","DOI":"10.1038\/s41598-022-22115-1","article-title":"Characterizing the composition of iPSC derived cells from bulk transcriptomics data with CellMap","volume":"12","author":"Ouyang","year":"2022","journal-title":"Sci Rep"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006229","article-title":"Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs","volume":"136","author":"Fidanza","year":"2020","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-835355","article-title":"New insights into hematopoietic differentiation landscapes from single-cell RNA sequencing","volume":"133","author":"Watcham","year":"2019","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41467-022-30557-4","article-title":"Robust temporal map of human in vitro myelopoiesis using single-cell genomics","volume":"13","author":"Alsinet","year":"2022","journal-title":"Nat Commun"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.658862","article-title":"Single-cell RNA sequencing of human pluripotent stem cell-derived macrophages for quality control of the cell therapy product","volume":"12","author":"Jo","year":"2022","journal-title":"Front Genet"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-191304","article-title":"Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells","volume":"114","author":"Kaufman","year":"2009","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1387\/ijdb.160274id","article-title":"Teratomas produced from human pluripotent stem cells xenografted into immunodeficient mice - a histopathology atlas","volume":"60","author":"Damjanov","year":"2016","journal-title":"Int J Dev Biol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-434407","article-title":"In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells","volume":"121","author":"Amabile","year":"2013","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.71","article-title":"Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2018.09.010","article-title":"Human teratoma-derived hematopoiesis is a highly polyclonal process supported by human umbilical vein endothelial cells","volume":"11","author":"Philipp","year":"2018","journal-title":"Stem Cell Rep"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.09.002","article-title":"Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors","volume":"13","author":"Doulatov","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718446115","article-title":"Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor","volume":"115","author":"Tan","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah5645","article-title":"Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors","volume":"9","author":"Doulatov","year":"2017","journal-title":"Sci Transl Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2018.03.020","article-title":"Dissecting the contributions of cooperating gene mutations to cancer phenotypes and drug responses with patient-derived iPSCs","volume":"10","author":"Chang","year":"2018","journal-title":"Stem Cell Rep"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02360-7","article-title":"Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells","volume":"43","author":"Ng","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-024-02172-2","article-title":"Generation of complex bone marrow organoids from human induced pluripotent stem cells","volume":"21","author":"Frenz-Wiessner","year":"2024","journal-title":"Nat Methods"},{"key":"B153","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/bloodadvances.2024013361","article-title":"Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment","volume":"9","author":"Ren","year":"2025","journal-title":"Blood Adv"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-13-713","article-title":"Differences in enhancer activity in mouse and zebrafish reporter assays are often associated with changes in gene expression","volume":"13","author":"Ariza-Cosano","year":"2012","journal-title":"BMC Genomics"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02243","article-title":"Modeling hematological diseases and cancer with patient-specific induced pluripotent stem cells","volume":"9","author":"Kim","year":"2018","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00250","article-title":"Novel genome-editing tools to model and correct primary immunodeficiencies","volume":"6","author":"Ott De Bruin","year":"2015","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2013.083873","article-title":"Genetic correction of HAX1 in induced pluripotent stem cells from a patient with severe congenital neutropenia improves defective granulopoiesis","volume":"99","author":"Morishima","year":"2014","journal-title":"Haematologica"},{"key":"B158","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/bjh.18477","article-title":"Truncated CSF3 receptors induce pro\u2010inflammatory responses in severe congenital neutropenia","volume":"200","author":"Olofsen","year":"2023","journal-title":"Br J Haematol"},{"key":"B159","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-0290-4_27","article-title":"CRISPR\/Cas9 genome editing of human-induced pluripotent stem cells followed by granulocytic differentiation","volume-title":"RNA Interference and CRISPR Technologies","author":"Dannenmann","year":"2020"},{"key":"B160","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3324\/haematol.2019.221804","article-title":"CRISPR\/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients","volume":"105","author":"Nasri","year":"2020","journal-title":"Haematologica"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.037","article-title":"CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia","volume":"32","author":"Nasri","year":"2024","journal-title":"Mol Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101626","article-title":"Targeted inhibition of ELANE expression using adenine base editing to treat severe congenital neutropenia","volume":"33","author":"Findik","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2024.0006","article-title":"Comparison of gene-editing approaches for severe congenital neutropenia-causing mutations in the ELANE gene","volume":"7","author":"Ritter","year":"2024","journal-title":"CRISPR J"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2013.04.002","article-title":"Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction","volume":"12","author":"Tulpule","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017764","article-title":"The spectrum of GATA2 deficiency syndrome","volume":"141","author":"Calvo","year":"2023","journal-title":"Blood"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017137","article-title":"GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells","volume":"2","author":"Jung","year":"2018","journal-title":"Blood Adv"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2024.103479","article-title":"Generation of iPSC lines and isogenic gene-corrected lines from two individuals with RPS19-mutated Diamond-Blackfan anemia syndrome","volume":"79","author":"Osuna","year":"2024","journal-title":"Stem Cell Res"},{"key":"B168","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cell.2018.02.036","article-title":"Ribosome levels selectively regulate translation and lineage commitment in human hematopoiesis","volume":"173","author":"Khajuria","year":"2018","journal-title":"Cell"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001593","article-title":"An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation","volume":"4","author":"Marion","year":"2020","journal-title":"Blood Adv"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nature25154","article-title":"Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells","volume":"553","author":"Garaycoechea","year":"2018","journal-title":"Nature"},{"key":"B171","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/acs.chemrestox.3c00045","article-title":"Aldehyde-associated mutagenesis\u2500current state of knowledge","volume":"36","author":"Vijayraghavan","year":"2023","journal-title":"Chem Res Toxicol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1595897","article-title":"CRISPR\/Cas-edited iPSCs and mesenchymal stem cells: a concise review of their potential in thalassemia therapy","volume":"13","author":"Shu","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1038\/s41467-022-32205-3","article-title":"Connecting omics signatures and revealing biological mechanisms with iLINCS","volume":"13","author":"Pilarczyk","year":"2022","journal-title":"Nat Commun"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.10.031","article-title":"Flavopiridol restores granulopoiesis in experimental models of severe congenital neutropenia","volume":"33","author":"Nasri","year":"2025","journal-title":"Mol Ther"},{"key":"B176","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13287-025-04427-x","article-title":"Repurposing of an inotropic drug dobutamine to enhance the production of human hematopoietic stem cells from human induced pluripotent stem cells","volume":"16","author":"Laowtammathron","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231845","article-title":"Generation of iPSCs from cultured human Malignant cells","volume":"115","author":"Carette","year":"2010","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217406","article-title":"Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders","volume":"114","author":"Ye","year":"2009","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3178","article-title":"Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells","volume":"33","author":"Kotini","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2655","article-title":"Brief report: Human acute myeloid leukemia reprogramming to pluripotency is a rare event and selects for patient hematopoietic cells devoid of leukemic mutations","volume":"35","author":"Lee","year":"2017","journal-title":"Stem Cells"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2019.101587","article-title":"Two iPSC lines generated from the bone marrow of a relapsed\/refractory AML patient display normal karyotypes and myeloid differentiation potential","volume":"41","author":"Yamasaki","year":"2019","journal-title":"Stem Cell Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2207","article-title":"Letter to the editor: Production of mature healthy hematopoietic cells from induced pluripotent stem cells derived from an AML diagnostic sample containing the t(8;21) translocation","volume":"34","author":"Hoffmann","year":"2016","journal-title":"Stem Cells"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884338","article-title":"Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes","volume":"134","author":"Hsu","year":"2019","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: Challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","article-title":"Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014965","article-title":"Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes","volume":"9","author":"Sarchi","year":"2025","journal-title":"Blood Adv"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1182\/bloodadvances.2021006325","article-title":"Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1 -mutant HSPCs","volume":"6","author":"Asimomitis","year":"2022","journal-title":"Blood Adv"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0508","article-title":"Integrative RNA-omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor\u2013mutant neoplasms","volume":"12","author":"Wheeler","year":"2022","journal-title":"Cancer Discov"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181394","article-title":"PPIL2 is a target of the JAK2\/STAT5 pathway and promotes myeloproliferation via degradation of p53","volume":"135","author":"Wang","year":"2025","journal-title":"J Clin Invest"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142149","article-title":"Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS\/AML","volume":"6","author":"Tothova","year":"2021","journal-title":"JCI Insight"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0230","article-title":"Mis-splicing of mitotic regulators sensitizes SF3B1-mutated human HSCs to CHK1 inhibition","volume":"5","author":"Sarchi","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000620","article-title":"Studying clonal evolution of myeloid Malignancies using induced pluripotent stem cells","volume":"28","author":"Doulatov","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2021.102195","article-title":"Induced pluripotent stem cell models of myeloid Malignancies and clonal evolution","volume":"52","author":"Reilly","year":"2021","journal-title":"Stem Cell Res"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034868","article-title":"Modeling leukemia with human induced pluripotent stem cells","volume":"9","author":"Papapetrou","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B196","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.stemcr.2023.12.003","article-title":"Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers","volume":"19","author":"Pizzato","year":"2024","journal-title":"Stem Cell Rep"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.59","article-title":"HLA engineering of human pluripotent stem cells","volume":"21","author":"Riolobos","year":"2013","journal-title":"Mol Ther"},{"key":"B198","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13287-024-03810-4","article-title":"Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity","volume":"15","author":"Tsuneyoshi","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01422-3","article-title":"Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout","volume":"57","author":"Kim","year":"2025","journal-title":"Exp Mol Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.01.011","article-title":"Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells","volume":"14","author":"Nakamura","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008512","article-title":"Production and nonclinical evaluation of an autologous iPSC\u2013derived platelet product for the iPLAT1 clinical trial","volume":"6","author":"Sugimoto","year":"2022","journal-title":"Blood Adv"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017296","article-title":"iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study","volume":"140","author":"Sugimoto","year":"2022","journal-title":"Blood"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03512-8","article-title":"Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets","volume":"117","author":"Chen","year":"2023","journal-title":"Int J Hematol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.stemcr.2019.11.011","article-title":"iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity","volume":"14","author":"Suzuki","year":"2020","journal-title":"Stem Cell Rep"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504725","article-title":"Large\u2010scale production of transfusion\u2010ready red blood cells from induced pluripotent stem cells","volume":"12","author":"Varga","year":"2025","journal-title":"Adv Sci"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1186\/s13619-025-00227-z","article-title":"Human induced pluripotent stem cells derived neutrophils display strong anti-microbial potencies","volume":"14","author":"Hu","year":"2025","journal-title":"Cell Regener"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201708-1562OC","article-title":"Pulmonary transplantation of human induced pluripotent stem cell\u2013derived macrophages ameliorates pulmonary alveolar proteinosis","volume":"198","author":"Happle","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B211","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.stemcr.2018.07.006","article-title":"iPSC-derived macrophages effectively treat pulmonary alveolar proteinosis in Csf2rb-deficient mice","volume":"11","author":"Mucci","year":"2018","journal-title":"Stem Cell Rep"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004853","article-title":"Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model","volume":"5","author":"Rafiei Hashtchin","year":"2021","journal-title":"Blood Adv"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202417848","article-title":"Human iPSC\u2010derived mononuclear phagocytes improve cognition and neural health across multiple mouse models of aging and Alzheimer\u2019s disease","volume":"12","author":"Moser","year":"2025","journal-title":"Adv Sci"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70341","article-title":"Comparing functional consequences of human iPSC\u2010microglia and neural stem cell\u2010derived extracellular vesicles in mitigating cognitive decline in Alzheimer\u2019s disease","volume":"25","author":"Krattli","year":"2026","journal-title":"Aging Cell"},{"key":"B215","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.stem.2025.03.009","article-title":"Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins","volume":"32","author":"Chadarevian","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300366120","article-title":"Targeted glycan degradation potentiates cellular immunotherapy for solid tumors","volume":"120","author":"Wu","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B220","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B221","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"NPJ Precis Onc"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.039321","article-title":"Modeling blood diseases with human induced pluripotent stem cells","volume":"12","author":"Georgomanoli","year":"2019","journal-title":"Dis Models Mech"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.100","article-title":"An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells","volume":"23","author":"Yagyu","year":"2015","journal-title":"Mol Ther"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.1c01536","article-title":"Developer\u2019s guide to an organ-on-chip model","volume":"8","author":"Rogal","year":"2022","journal-title":"ACS Biomater Sci Eng"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.14573\/altex.2001241","article-title":"Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development","volume":"37","author":"Marx","year":"2020","journal-title":"ALTEX"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243840","article-title":"Microfluidics and organ-on-a-chip technologies: a systematic review of the methods used to mimic bone marrow","volume":"15","author":"Santos Rosalem","year":"2020","journal-title":"PloS One"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2938","article-title":"Bone marrow\u2013on\u2013a\u2013chip replicates hematopoietic niche physiology in vitro","volume":"11","author":"Torisawa","year":"2014","journal-title":"Nat Methods"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1002\/term.2507","article-title":"Bone marrow\u2010on\u2010a\u2010chip: long\u2010term culture of human haematopoietic stem cells in a three\u2010dimensional microfluidic environment","volume":"12","author":"Sieber","year":"2018","journal-title":"J Tissue Eng Regener Med"},{"key":"B229","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s42003-025-08137-1","article-title":"A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development","volume":"8","author":"Koenig","year":"2025","journal-title":"Commun Biol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121245","article-title":"Organ-on-a-chip model of vascularized human bone marrow niches","volume":"280","author":"Glaser","year":"2022","journal-title":"Biomaterials"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1038\/nature09805","article-title":"Somatic coding mutations in human induced pluripotent stem cells","volume":"471","author":"Gore","year":"2011","journal-title":"Nature"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1011","article-title":"Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells","volume":"30","author":"Ji","year":"2012","journal-title":"Stem Cells"},{"key":"B233","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stemcr.2013.11.006","article-title":"Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells","volume":"2","author":"Sugiura","year":"2014","journal-title":"Stem Cell Rep"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1038\/nature22312","article-title":"Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations","volume":"545","author":"Merkle","year":"2017","journal-title":"Nature"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2051","article-title":"Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage","volume":"29","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41598-020-60466-9","article-title":"Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivatives","volume":"10","author":"Jo","year":"2020","journal-title":"Sci Rep"},{"key":"B237","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.stem.2012.02.014","article-title":"Erosion of dosage compensation impacts human iPSC disease modeling","volume":"10","author":"Mekhoubad","year":"2012","journal-title":"Cell Stem Cell"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1038\/nature09017","article-title":"Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells","volume":"465","author":"Stadtfeld","year":"2010","journal-title":"Nature"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2016.06.019","article-title":"Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity","volume":"19","author":"Nishizawa","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1038\/nature22370","article-title":"Haematopoietic stem and progenitor cells from human pluripotent stem cells","volume":"545","author":"Sugimura","year":"2017","journal-title":"Nature"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1716145","article-title":"Stem cells in the treatment of disease","volume":"380","author":"Blau","year":"2019","journal-title":"N Engl J Med"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0247","article-title":"Hematopoietic stem cells from pluripotent stem cells: clinical potential, challenges, and future perspectives","volume":"9","author":"Demirci","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"B243","doi-asserted-by":"publisher","first-page":"895","DOI":"10.4049\/jimmunol.2200836","article-title":"Three-dimensional human bone marrow organoids for the study and application of normal and abnormal hematoimmunopoiesis","volume":"210","author":"De Janon","year":"2023","journal-title":"J Immunol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105171","article-title":"Digital twins in oncology: from predictive modelling to personalised treatment strategies","volume":"220","author":"Olawade","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B245","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2021012652","article-title":"Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome","volume":"139","author":"Clough","year":"2022","journal-title":"Blood"},{"key":"B246","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3324\/haematol.2018.208488","article-title":"Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia","volume":"105","author":"Beke","year":"2020","journal-title":"Haematologica"},{"key":"B247","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/leu.2014.136","article-title":"Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD\/AML patients","volume":"28","author":"Sakurai","year":"2014","journal-title":"Leukemia"},{"key":"B248","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.exphem.2015.05.004","article-title":"Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis","volume":"43","author":"Iizuka","year":"2015","journal-title":"Exp Hematol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood-2014-06-585513","article-title":"Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia","volume":"125","author":"Antony-Debr\u00e9","year":"2015","journal-title":"Blood"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107688","article-title":"Acute myeloid leukemia iPSCs reveal a role for RUNX1 in the maintenance of human leukemia stem cells","volume":"31","author":"Wesely","year":"2020","journal-title":"Cell Rep"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125157","article-title":"Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells","volume":"4","author":"Ruiz-Guti\u00e9rrez","year":"2019","journal-title":"JCI Insight"},{"key":"B252","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/2159-8290.CD-24-1604","article-title":"DNMT3A R882H is not required for disease maintenance in primary human AML but is associated with increased leukemia stem cell frequency","volume":"16","author":"K\u00f6hnke","year":"2026","journal-title":"Cancer Discov"},{"key":"B253","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.stem.2022.02.010","article-title":"Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function","volume":"29","author":"Reilly","year":"2022","journal-title":"Cell Stem Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:21:59Z","timestamp":1784089319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1815809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":253,"alternative-id":["10.3389\/fimmu.2026.1815809"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1815809","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1815809"}}